Clinical Trials Logo

Clinical Trial Summary

Oligodendrogliomas represent a distinct subgroup of adult gliomas characterized by specific molecular alterations (1p/19q codeletion, mutations of IDH, TERT promoter, CIC, FUBP1). These tumors account for 5 to 10% of adult gliomas and are of special relevance in the neuro-oncology field because of their frequent chemosensitivity (Louis et al. 2016). The genetics of oligodendrogliomas is relatively well characterized but the mechanisms of oncogenesis for these tumors are poorly understood. Although oligodendrogliomas prognosis is usually better than that of other adult glioma subtypes, it remains heterogeneous and there is no effective treatment at recurrence after radiotherapy and chemotherapy. Our recent work conducted within the INCa-funded national POLA network has related this clinical heterogeneity to inter-tumoral heterogeneity. Based on a transcriptomic analysis of a large series of oligodendroglial gliomas we identified 3 subgroups, the most aggressive group being characterized by aggressive clinical and molecular pattern. Recent studies, however, have shown a relatively low level of concordance between mRNA and protein expression, emphasizing the need to use proteomic-based approaches to better understand tumor biology. Taking advantage of the POLA cohort, we propose to expand our previous analysis by integrating a proteomic analysis of oligodendrogliomas. The aim of this project is to identify drivers of oligodendroglioma subgroups, among which potential druggable targets (i.e receptors, metabolism effectors). For this purpose, the proteomic profiles of 90 oligodendrogliomas will be generated and integrated with transcriptomic, genomic and methylation profiles in order to identify signaling pathways specifically associated with each subtype, especially with the most aggressive one. Associations will be explored between candidate signaling pathways expression and clinical outcomes (survival, progression-free survival, objective response). The relevance of the 2 most promising candidate signaling pathways will be assessed in vitro and in vivo using genetically relevant mouse and xenograft models. Our project will identify targetable oncogenic pathways associated with poor prognosis that could lead to new therapeutic strategies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04843085
Study type Observational
Source Hospices Civils de Lyon
Contact François DUCRAY, MD
Phone 04 72 35 78 06
Email francois.ducray@chu-lyon.fr
Status Recruiting
Phase
Start date September 30, 2020
Completion date September 2023

See also
  Status Clinical Trial Phase
Terminated NCT02764151 - First in Patient Study for PF-06840003 in Malignant Gliomas Phase 1
Completed NCT02903784 - Neural Basis of Language Processing N/A
Completed NCT00165360 - Prolonged Daily Temozolomide for Low-Grade Glioma Phase 2
Recruiting NCT04541082 - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Phase 1
Completed NCT02530320 - Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Phase 2
Terminated NCT00389090 - A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Phase 2
Active, not recruiting NCT02549833 - Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma Phase 1
Recruiting NCT06038760 - Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Recruiting NCT05624736 - Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Recruiting NCT05345002 - All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma Phase 2
Completed NCT03900689 - Social Determinants of Health in Glioblastoma Population
Completed NCT02747407 - Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
Recruiting NCT04970615 - Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Terminated NCT01836549 - Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Phase 2
Recruiting NCT03796273 - Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases Early Phase 1
Terminated NCT00031538 - Genetic Analysis of Brain Tumors
Completed NCT01609790 - Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors Phase 2
Not yet recruiting NCT05513859 - Investigational Imaging Technique During Brain Surgery N/A
Not yet recruiting NCT06161974 - Study of Olutasidenib and Temozolomide in HGG Phase 2